<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01908842</url>
  </required_header>
  <id_info>
    <org_study_id>OX219-006 Protocol Amendment 4</org_study_id>
    <nct_id>NCT01908842</nct_id>
  </id_info>
  <brief_title>Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults</brief_title>
  <acronym>ISTART</acronym>
  <official_title>Induction, STabilization, Adherence, and Retention Trial (ISTART) - A Randomized, Non-inferiority, Multicenter Study to Assess Early Treatment Efficacy of OX219 Versus SUBOXONE Film and to Explore Switching Between Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orexo AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Orexo AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess retention in treatment after induction with
      buprenorphine/naloxone (BNX) sublingual tablets compared with generic buprenorphine and after
      stabilization with BNX sublingual tablets compared with BNX film. Secondary objectives
      included assessment of treatment effects on opioid withdrawal symptoms, opioid cravings, and
      safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, randomized, multicenter, parallel-group, non-inferiority study was
      conducted at 43 centers in the United States from August 2013 to April 2014. A non-inferior
      design was used because both products contain the same active components, and it was
      considered unethical to include a placebo arm. The study comprised an induction phase of 2
      days and a stabilization phase of 20 days, with study visits scheduled on Days 1, 2, 3, 4, 8,
      15, and 22. Eligible opioid-dependent patients were randomly assigned within 14 days of
      screening to induction with either the BNX sublingual tablets or generic buprenorphine
      tablets for 2 days. On Day 3, patients initially allocated to buprenorphine were switched to
      BNX film, whereas those allocated to BNX sublingual tablets continued on the same treatment.
      On Day 15, patients receiving BNX film were switched to BNX sublingual tablets, and those on
      BNX sublingual tablets were switched to BNX film. At the final study visit on Day 22,
      patients were offered the option of continuing in an open-label follow-up study of BNX
      sublingual tablets.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoints of Retention in Treatment at Days 3 and 15</measure>
    <time_frame>Day 3 and Day 15</time_frame>
    <description>Retention rates (number of patients retained) for the primary efficacy endpoints of retention in treatment at Days 3 and 15, which was defined as the number of patients who received treatment on Days 3 and 15.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Opiate Withdrawal Scale (COWS) Scores: Induction</measure>
    <time_frame>Days 1 and 2</time_frame>
    <description>Absolute ± mean standard deviation values for COWS total scores at baseline; 0.5 h, 1.5 h, 3 h, and 6 h post dose on Day 1, and Day 2; COWS scores range from 0-48, with a lower score being more favorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COWS Total Scores: Stabilization/Maintenance</measure>
    <time_frame>Days 3 through 22</time_frame>
    <description>Absolute ± mean standard deviation values for COWS total scores at Days 3, 4, 8, 15, and 22; COWS scores range from 0-48, with a lower score being more favorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Opiate Withdrawal Scale (SOWS) Scores: Induction</measure>
    <time_frame>Days 1 and 2</time_frame>
    <description>Absolute ± mean standard deviation values for SOWS total scores at baseline, 0.5 h, 1.5 h, 3 h, and 6 h post dose on Day 1, and Day 2; SOWS score ranges from 0-64, with a lower score being more favorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOWS Total Scores: Stabilization/Maintenance</measure>
    <time_frame>Days 3 through 22</time_frame>
    <description>Absolute ± mean standard deviation values for SOWS total scores on Days 2, 3, 4, 8, 15, and 22; SOWS scores ranged from 0-64, with a lower score being more favorable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) Cravings: Induction</measure>
    <time_frame>Days 1 and 2</time_frame>
    <description>Absolute mean ± standard deviation values for VAS cravings at baseline, 0.5 h, 1.5 h, 3 h, and 6 post dose on Day 1, and Day 2; the VAS craving scores range from 0 (&quot;no cravings&quot;) to 100 (&quot;most intense craving I have ever had&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Craving Scores: Stabilization/Maintenance</measure>
    <time_frame>Days 3 through 22</time_frame>
    <description>Absolute mean ± standard deviation values for VAS cravings scores on Days 3, 4, 8, 15, and 22; the VAS craving scores range from 0 (&quot;no cravings&quot;) to 100 (&quot;most intense craving I have ever had&quot;)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">759</enrollment>
  <condition>Opioid Dependence, on Agonist Therapy</condition>
  <arm_group>
    <arm_group_label>Buprenorphine; then OL BNX film, then BNX tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Days 1-2: Generic buprenorphine sublingual tablets (blinded); Days 3 to 14: Buprenorphine/naloxone sublingual film (open-label); Days 15-21: BNX sublingual tablets (open-label); Day 22: Offered option in continuing in open-label follow-up study of BNX sublingual tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BNX tablets, then OL BNX tablets, then BNX film</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 1-2: BNX sublingual tablets (blinded); Days 3 to 14: BNX sublingual tablets (open-label); Days 15-21: Buprenorphine/naloxone sublingual film (open-label); Day 22: Offered option in continuing in open-label follow-up study of BNX sublingual tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BNX sublingual tablets</intervention_name>
    <description>Buprenorphine/naloxone sublingual tablets</description>
    <arm_group_label>Buprenorphine; then OL BNX film, then BNX tablets</arm_group_label>
    <arm_group_label>BNX tablets, then OL BNX tablets, then BNX film</arm_group_label>
    <other_name>OX219</other_name>
    <other_name>Zubsolv</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BNX sublingual film</intervention_name>
    <description>Buprenorphine/naloxone sublingual film</description>
    <arm_group_label>Buprenorphine; then OL BNX film, then BNX tablets</arm_group_label>
    <arm_group_label>BNX tablets, then OL BNX tablets, then BNX film</arm_group_label>
    <other_name>Suboxone film</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Buprenorphine sublingual tablets</description>
    <arm_group_label>Buprenorphine; then OL BNX film, then BNX tablets</arm_group_label>
    <other_name>Generic buprenorphine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male/female 18-65 years old

          2. Able to read, comprehend &amp; sign the informed consent form

          3. Meet opioid dependence criteria in DSM-IV-TR the past 12 months

          4. Have a buprenorphine-negative UDS &amp;/or urine dipstick

          5. Prepared to abstain from opioids other than the study drug &amp; from other addictive
             drugs

          6. Negative urine pregnancy test

          7. Females of childbearing potential who use a reliable method of contraception. Females
             of non-childbearing potential; surgically sterile or post-menopausal as defined by
             being at least 50 years of age &amp; having an absence of menses for at least 2 years

          8. Clearance from the prescribing MD to be withdrawn from their prescribed opioids for
             subjects receiving opioids for pain

          9. Lack of clinically significant abnormalities in health assessments performed at
             screening. Unclear cases should be approved by the medical monitor

         10. At least mild withdrawal symptoms (COWS ≥9)

        Exclusion Criteria:

          1. Pregnant, lactating or planning to be pregnant during study

          2. Unwilling/unable to comply with the requirements of the protocol (e.g., pending
             incarceration) are in a situation/condition that may interfere with participation in
             the study

          3. Prescribed treatment with generic buprenorphine monotherapy within 90 days prior start
             of treatment

          4. Daily dose of methadone over 30 mg during the past week or who received the last dose
             of methadone less than 30 hours prior to treatment

          5. Participating in other clinical studies in which medications is delivered or who have
             used an investigational drug/device within the last 30 days

          6. Allergy, sensitivity or intolerance to BUP, NAL or any related drug; history of drug
             hypersensitivity or intolerance which, in the opinion of the investigator, would
             compromise the safety of the subject/study

          7. Staff, affiliated with, or family member of the staff directly involved with this
             study

          8. Serious untreated Axis I DSM-IV-TR psychiatric comorbidity (actively suicidal or
             homicidal, have untreated schizophrenia)

          9. Tongue/oral deformities that may affect the absorption of the drug products

         10. Current/history of clinically significant medical disorder or condition which would
             jeopardize the safety or impact the validity of the results. Unclear cases should be
             discussed with &amp; approved by the medical monitor

         11. HIV-seropositive with a CD4+ count &lt;200, active AIDS defining infection in the last
             120 days

         12. Have Class III/IV congestive heart failure, symptomatic myocardial ischemia or history
             of long QT syndrome (or an immediate family member with this condition)

         13. Currently taking Class 1A antiarrhythmic medications (e.g., quinidine, procainamide, &amp;
             disopyramide) or Class III antiarrhythmic medications (e.g., sotalol, amiodarone, &amp;
             dofetilide)

         14. Have uncontrolled hypertension, pulse oximetry ≤92%or clinically significant
             abnormality on 12-lead ECG, including a corrected QT (QTc) interval &gt;450 ms

         15. Severe liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erik Gunderson</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia, PO Box 800623, Charlottesville, VA 22911</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Baldwin County</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston County</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maricopa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles County</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside County</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego County</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Broward County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colombia County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Duval County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greater Metro Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami-Dade County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osceola County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Beach County</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>DeKalb County</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicagoland</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johnson County</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kenton County</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caddo Parish</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore County</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol County</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis Metro Area</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camden County</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warren County</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warren County</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma County</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland metropolitan area</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Allegheny County</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delaware County</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia County</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston County</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas County</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake County</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville metropolitan area</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Benton County</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2013</study_first_submitted>
  <study_first_submitted_qc>July 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2013</study_first_posted>
  <results_first_submitted>April 8, 2015</results_first_submitted>
  <results_first_submitted_qc>May 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 22, 2015</results_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid</keyword>
  <keyword>Dependence</keyword>
  <keyword>agonist</keyword>
  <keyword>buprenorphine</keyword>
  <keyword>naloxone</keyword>
  <keyword>BUP/NAL</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 759 patients were enrolled. One patient who was randomized did not receive study drug, making the participant flow total 758.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BNX Tablets, Then OL BNX Tablets, Then BNX Film</title>
          <description>Days 1-2: BNX sublingual tablets (blinded induction); Days 3 to 14: BNX sublingual tablets (open-label stabilization/maintenance); Days 15-21: Switch to BNX sublingual film (open-label stabilization/maintenance); Day 22: End of study visit</description>
        </group>
        <group group_id="P2">
          <title>Buprenorphine, Then OL BNX Film, Then BNX Tablets</title>
          <description>Days 1-2: Buprenorphine (blinded induction); Days 3-14: BNX sublingual film (open-label stabilization/maintenance); Days 15-21: Switch to BNX sublingual tablets (open-label stabilization/maintenance); Day 22: End of study visit</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="383"/>
                <participants group_id="P2" count="375"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="357"/>
                <participants group_id="P2" count="344"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Switch to Other BNX Formulation (Day 15)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="357"/>
                <participants group_id="P2" count="344"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
                <participants group_id="P2" count="279"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Day 22: Film (Col 1); Tablets (Col 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="287"/>
                <participants group_id="P2" count="279"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="262"/>
                <participants group_id="P2" count="262"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BNX Tablets, Then OL BNX Tablets, Then BNX Film</title>
          <description>Days 1-2: BNX sublingual tablets (blinded); Days 3-14: BNX sublingual tablets (open-label); Days 15-21: Switch to BNX sublingual film (open-label); Day 22: End of study visit</description>
        </group>
        <group group_id="B2">
          <title>Buprenorphine, Then OL BNX Film, Then BNX Tablets</title>
          <description>Days 1-2: Generic buprenorphine sublingual tablets (blinded); Days 3 to 14: BNX sublingual film (open-label); Days 15-21: Switch to BNX sublingual tablets (open-label); Day 22: End of study visit</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="383"/>
            <count group_id="B2" value="375"/>
            <count group_id="B3" value="758"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.6" spread="11.3"/>
                    <measurement group_id="B2" value="35.7" spread="11.3"/>
                    <measurement group_id="B3" value="35.6" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="306"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="318"/>
                    <measurement group_id="B2" value="312"/>
                    <measurement group_id="B3" value="630"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.5" spread="9.3"/>
                    <measurement group_id="B2" value="172.3" spread="9.4"/>
                    <measurement group_id="B3" value="171.9" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.1" spread="18.7"/>
                    <measurement group_id="B2" value="78.3" spread="18.4"/>
                    <measurement group_id="B3" value="77.7" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.2" spread="5.9"/>
                    <measurement group_id="B2" value="26.3" spread="5.7"/>
                    <measurement group_id="B3" value="26.3" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of opioid use</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.7" spread="9.6"/>
                    <measurement group_id="B2" value="10.5" spread="9.0"/>
                    <measurement group_id="B3" value="10.6" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Opiate Withdrawal Scale (COWS) Scores: Induction</title>
        <description>Absolute ± mean standard deviation values for COWS total scores at baseline; 0.5 h, 1.5 h, 3 h, and 6 h post dose on Day 1, and Day 2; COWS scores range from 0-48, with a lower score being more favorable</description>
        <time_frame>Days 1 and 2</time_frame>
        <population>Full Analysis Population - number of enrolled patients at the beginning of the measurement period</population>
        <group_list>
          <group group_id="O1">
            <title>BNX Tablets, Then OL BNX Tablets, Then BNX Film</title>
            <description>Days 1-2: BNX sublingual tablets (blinded induction); Days 3-14: BNX sublingual tablets (open-label stabilization/maintenance); Days 15-21: Switch to BNX sublingual film (open-label stabilization/maintenance); Day 22: End of study visit</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine, Then OL BNX Film, Then BNX Tablets</title>
            <description>Days 1-2: Buprenorphine sublingual tablets (blinded induction); Days 3-14: BNX sublingual film (open-label stabilization/maintenance); Days 15-21: Switch to BNX sublingual tablets (open-label stabilization/maintenance); Day 22: End of study visit</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Opiate Withdrawal Scale (COWS) Scores: Induction</title>
          <description>Absolute ± mean standard deviation values for COWS total scores at baseline; 0.5 h, 1.5 h, 3 h, and 6 h post dose on Day 1, and Day 2; COWS scores range from 0-48, with a lower score being more favorable</description>
          <population>Full Analysis Population - number of enrolled patients at the beginning of the measurement period</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="380"/>
                <count group_id="O2" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="4.2"/>
                    <measurement group_id="O2" value="14.9" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 0.5 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="4.6"/>
                    <measurement group_id="O2" value="10.3" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 1.5 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="4.6"/>
                    <measurement group_id="O2" value="8.3" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 3 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="5.1"/>
                    <measurement group_id="O2" value="6.1" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 6 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="4.1"/>
                    <measurement group_id="O2" value="5.4" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="4.9"/>
                    <measurement group_id="O2" value="7.6" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COWS Total Scores: Stabilization/Maintenance</title>
        <description>Absolute ± mean standard deviation values for COWS total scores at Days 3, 4, 8, 15, and 22; COWS scores range from 0-48, with a lower score being more favorable</description>
        <time_frame>Days 3 through 22</time_frame>
        <population>Full analysis population - - number of enrolled patients at the beginning of the measurement period</population>
        <group_list>
          <group group_id="O1">
            <title>BNX Tablets, Then OL BNX Tablets, Then BNX Film</title>
            <description>Days 1-2: BNX sublingual tablets (blinded induction); Days 3-14: BNX sublingual tablets (open-label stabilization/maintenance); Days 15-21: Switch to BNX sublingual film (open-label stabilization/maintenance); Day 22: End of study visit</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine, Then OL BNX Film, Then BNX Tablets</title>
            <description>Days 1-2: Buprenorphine sublingual tablets (blinded induction); Days 3-14: BNX sublingual film (open-label stabilization/maintenance); Days 15-21: Switch to BNX sublingual tablets (open-label stabilization/maintenance); Day 22: End of study visit</description>
          </group>
        </group_list>
        <measure>
          <title>COWS Total Scores: Stabilization/Maintenance</title>
          <description>Absolute ± mean standard deviation values for COWS total scores at Days 3, 4, 8, 15, and 22; COWS scores range from 0-48, with a lower score being more favorable</description>
          <population>Full analysis population - - number of enrolled patients at the beginning of the measurement period</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="4.2"/>
                    <measurement group_id="O2" value="5.9" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="4.0"/>
                    <measurement group_id="O2" value="5.1" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="3.9"/>
                    <measurement group_id="O2" value="4.6" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="3.5"/>
                    <measurement group_id="O2" value="3.7" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22: Film (col 1); Tablets (col 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="3.3"/>
                    <measurement group_id="O2" value="3.3" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Opiate Withdrawal Scale (SOWS) Scores: Induction</title>
        <description>Absolute ± mean standard deviation values for SOWS total scores at baseline, 0.5 h, 1.5 h, 3 h, and 6 h post dose on Day 1, and Day 2; SOWS score ranges from 0-64, with a lower score being more favorable</description>
        <time_frame>Days 1 and 2</time_frame>
        <population>Full analysis population - number of enrolled patients at the beginning of the measurement period</population>
        <group_list>
          <group group_id="O1">
            <title>BNX Tablets, Then OL BNX Tablets, Then BNX Film</title>
            <description>Days 1-2: BNX sublingual tablets (blinded induction); Days 3-14: BNX sublingual tablets (open-label stabilization/maintenance); Days 15-21: Switch to BNX sublingual film (open-label stabilization/maintenance); Day 22: End of study visit</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine, Then OL BNX Film, Then BNX Tablets</title>
            <description>Days 1-2: Buprenorphine sublingual tablets (blinded induction); Days 3-14: BNX sublingual film (open-label stabilization/maintenance); Days 15-21: Switch to BNX sublingual tablets (open-label stabilization/maintenance); Day 22: End of study visit</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Opiate Withdrawal Scale (SOWS) Scores: Induction</title>
          <description>Absolute ± mean standard deviation values for SOWS total scores at baseline, 0.5 h, 1.5 h, 3 h, and 6 h post dose on Day 1, and Day 2; SOWS score ranges from 0-64, with a lower score being more favorable</description>
          <population>Full analysis population - number of enrolled patients at the beginning of the measurement period</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="367"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.7" spread="13.5"/>
                    <measurement group_id="O2" value="33.0" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 0.5 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="13.9"/>
                    <measurement group_id="O2" value="23.0" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 1.5 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" spread="13.5"/>
                    <measurement group_id="O2" value="17.8" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 3 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="12.7"/>
                    <measurement group_id="O2" value="13.0" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 6 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="10.2"/>
                    <measurement group_id="O2" value="11.1" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="12.3"/>
                    <measurement group_id="O2" value="16.4" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Endpoints of Retention in Treatment at Days 3 and 15</title>
        <description>Retention rates (number of patients retained) for the primary efficacy endpoints of retention in treatment at Days 3 and 15, which was defined as the number of patients who received treatment on Days 3 and 15.</description>
        <time_frame>Day 3 and Day 15</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>BNX Tablets, Then OL BNX Tablets, Then BNX Film</title>
            <description>Days 1-2: BNX sublingual tablets (blinded induction); Days 3-14: BNX sublingual tablets (open-label stabilization/maintenance); Days 15-21: Switch to BNX sublingual film (open-label stabilization/maintenance); Day 22: End of study visit</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine, Then OL BNX Film, Then BNX Tablets</title>
            <description>Days 1-2: Buprenorphine sublingual tablets (blinded induction); Days 3-14: BNX sublingual film (open-label stabilization/maintenance); Days 15-21: Switch to BNX sublingual tablets (open-label stabilization/maintenance); Day 22: End of study visit</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Endpoints of Retention in Treatment at Days 3 and 15</title>
          <description>Retention rates (number of patients retained) for the primary efficacy endpoints of retention in treatment at Days 3 and 15, which was defined as the number of patients who received treatment on Days 3 and 15.</description>
          <population>Per protocol population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Retention at Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309"/>
                    <measurement group_id="O2" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retention at Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273"/>
                    <measurement group_id="O2" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SOWS Total Scores: Stabilization/Maintenance</title>
        <description>Absolute ± mean standard deviation values for SOWS total scores on Days 2, 3, 4, 8, 15, and 22; SOWS scores ranged from 0-64, with a lower score being more favorable</description>
        <time_frame>Days 3 through 22</time_frame>
        <population>Full Analysis Population - number of enrolled patients at the beginning of the measurement period</population>
        <group_list>
          <group group_id="O1">
            <title>BNX Tablets, Then OL BNX Tablets, Then BNX Film</title>
            <description>Days 1-2: BNX sublingual tablets (blinded induction); Days 3-14: BNX sublingual tablets (open-label stabilization/maintenance); Days 15-21: Switch to BNX sublingual film (open-label stabilization/maintenance); Day 22: End of study visit</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine, Then OL BNX Film, Then BNX Tablets</title>
            <description>Days 1-2: Buprenorphine sublingual tablets (blinded induction); Days 3-14: BNX sublingual film (open-label stabilization/maintenance); Days 15-21: Switch to BNX sublingual tablets (open-label stabilization/maintenance); Day 22: End of study visit</description>
          </group>
        </group_list>
        <measure>
          <title>SOWS Total Scores: Stabilization/Maintenance</title>
          <description>Absolute ± mean standard deviation values for SOWS total scores on Days 2, 3, 4, 8, 15, and 22; SOWS scores ranged from 0-64, with a lower score being more favorable</description>
          <population>Full Analysis Population - number of enrolled patients at the beginning of the measurement period</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="355"/>
                <count group_id="O2" value="342"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="10.4"/>
                    <measurement group_id="O2" value="12.6" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" spread="9.2"/>
                    <measurement group_id="O2" value="10.2" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="9.2"/>
                    <measurement group_id="O2" value="8.8" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="7.7"/>
                    <measurement group_id="O2" value="6.7" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22: Film (col 1); Tablets (col 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="7.9"/>
                    <measurement group_id="O2" value="7.3" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analog Scale (VAS) Cravings: Induction</title>
        <description>Absolute mean ± standard deviation values for VAS cravings at baseline, 0.5 h, 1.5 h, 3 h, and 6 post dose on Day 1, and Day 2; the VAS craving scores range from 0 (&quot;no cravings&quot;) to 100 (&quot;most intense craving I have ever had&quot;)</description>
        <time_frame>Days 1 and 2</time_frame>
        <population>Full Analysis Population - number of enrolled patients at the beginning of the measurement period</population>
        <group_list>
          <group group_id="O1">
            <title>BNX Tablets, Then OL BNX Tablets, Then BNX Film</title>
            <description>Days 1-2: BNX sublingual tablets (blinded induction); Days 3-14: BNX sublingual tablets (open-label stabilization/maintenance); Days 15-21: Switch to BNX sublingual film (open-label stabilization/maintenance); Day 22: End of study visit</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine, Then OL BNX Film, Then BNX Tablets</title>
            <description>Days 1-2: Buprenorphine sublingual tablets (blinded induction); Days 3-14: BNX sublingual film (open-label stabilization/maintenance); Days 15-21: Switch to BNX sublingual tablets (open-label stabilization/maintenance); Day 22: End of study visit</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale (VAS) Cravings: Induction</title>
          <description>Absolute mean ± standard deviation values for VAS cravings at baseline, 0.5 h, 1.5 h, 3 h, and 6 post dose on Day 1, and Day 2; the VAS craving scores range from 0 (&quot;no cravings&quot;) to 100 (&quot;most intense craving I have ever had&quot;)</description>
          <population>Full Analysis Population - number of enrolled patients at the beginning of the measurement period</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="380"/>
                <count group_id="O2" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2" spread="23.5"/>
                    <measurement group_id="O2" value="71.9" spread="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 0.5 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" spread="26.5"/>
                    <measurement group_id="O2" value="58.2" spread="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 1.5 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" spread="28.9"/>
                    <measurement group_id="O2" value="48.8" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 3 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0" spread="28.2"/>
                    <measurement group_id="O2" value="34.9" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 6 h post dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" spread="26.2"/>
                    <measurement group_id="O2" value="29.6" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3" spread="28.7"/>
                    <measurement group_id="O2" value="44.9" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VAS Craving Scores: Stabilization/Maintenance</title>
        <description>Absolute mean ± standard deviation values for VAS cravings scores on Days 3, 4, 8, 15, and 22; the VAS craving scores range from 0 (&quot;no cravings&quot;) to 100 (&quot;most intense craving I have ever had&quot;)</description>
        <time_frame>Days 3 through 22</time_frame>
        <population>Full analysis population - number of enrolled patients at the beginning of the measurement period</population>
        <group_list>
          <group group_id="O1">
            <title>BNX Tablets, Then OL BNX Tablets, Then BNX Film</title>
            <description>Days 1-2: BNX sublingual tablets (blinded induction); Days 3-14: BNX sublingual tablets (open-label stabilization/maintenance); Days 15-21: Switch to BNX sublingual film (open-label stabilization/maintenance); Day 22: End of study visit</description>
          </group>
          <group group_id="O2">
            <title>Buprenorphine, Then OL BNX Film, Then BNX Tablets</title>
            <description>Days 1-2: Buprenorphine sublingual tablets (blinded induction); Days 3-14: BNX sublingual film (open-label stabilization/maintenance); Days 15-21: Switch to BNX sublingual tablets (open-label stabilization/maintenance); Day 22: End of study visit</description>
          </group>
        </group_list>
        <measure>
          <title>VAS Craving Scores: Stabilization/Maintenance</title>
          <description>Absolute mean ± standard deviation values for VAS cravings scores on Days 3, 4, 8, 15, and 22; the VAS craving scores range from 0 (&quot;no cravings&quot;) to 100 (&quot;most intense craving I have ever had&quot;)</description>
          <population>Full analysis population - number of enrolled patients at the beginning of the measurement period</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="356"/>
                <count group_id="O2" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" spread="27.0"/>
                    <measurement group_id="O2" value="34.5" spread="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" spread="26.2"/>
                    <measurement group_id="O2" value="28.5" spread="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" spread="26.5"/>
                    <measurement group_id="O2" value="23.7" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="23.9"/>
                    <measurement group_id="O2" value="19.1" spread="23.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 22: Film (col 1); Tablets (col 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" spread="22.9"/>
                    <measurement group_id="O2" value="20.9" spread="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Monitoring for adverse events was conducted from baseline through Day 22.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BNX Tablets, Then OL BNX Tablets, Then BNX Film</title>
          <description>Days 1-2: BNX sublingual tablets (blinded induction); Days 3-14: BNX sublingual tablets (open-label stabilization/maintenance); Days 15-21: Switch to BNX sublingual film (open-label stabilization/maintenance); Day 22: End of study visit</description>
        </group>
        <group group_id="E2">
          <title>Buprenorphine, Then OL BNX Film, Then BNX Tablets</title>
          <description>Days 1-2: Buprenorphine sublingual tablets (blinded induction); Days 3-14: BNX sublingual film (open-label stabilization/maintenance); Days 15-21: Switch to BNX sublingual tablets (open-label stabilization/maintenance); Day 22: End of study visit</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Transaminases</sub_title>
                <description>Serious adverse event reported during open-label maintenance phase.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Worsening of pre-existing condition (foreign body in neck)</sub_title>
                <description>Serious adverse event reported during blinded induction phase.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <description>Serious adverse event reported during blinded induction phase.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="383"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <description>Serious adverse event reported during open-label maintenance phase.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="383"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="383"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Adverse events reported during the blinded induction phase.</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="383"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Adverse events reported during the blinded induction phase.</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="383"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <description>Adverse events reported during the blinded induction phase.</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="383"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Adverse events reported during the blinded induction phase.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="383"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Adverse events reported during the blinded induction phase.</description>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="383"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="375"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <description>Adverse events reported during the blinded induction phase.</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="383"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Adverse events reported during the blinded induction phase.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="383"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="375"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Erik Gunderson, MD, FASAM</name_or_title>
      <organization>University of Virginia</organization>
      <phone>(434) 202-8612</phone>
      <email>EWG2N@hscmail.mcc.virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

